GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LENZ Therapeutics Inc (NAS:LENZ) » Definitions » Net Income From Continuing Operations

LENZ (LENZ Therapeutics) Net Income From Continuing Operations : $-47.74 Mil (TTM As of Mar. 2025)


View and export this data going back to 2024. Start your Free Trial

What is LENZ Therapeutics Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. LENZ Therapeutics's net income from continuing operations for the three months ended in Mar. 2025 was $-14.62 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Mar. 2025 was $-47.74 Mil.


LENZ Therapeutics Net Income From Continuing Operations Historical Data

The historical data trend for LENZ Therapeutics's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LENZ Therapeutics Net Income From Continuing Operations Chart

LENZ Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Net Income From Continuing Operations
-7.56 -10.81 -69.97 -49.77

LENZ Therapeutics Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Net Income From Continuing Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -16.65 -10.25 -10.22 -12.65 -14.62

LENZ Therapeutics Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-47.74 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


LENZ Therapeutics Business Description

Industry
Traded in Other Exchanges
N/A
Address
201 Lomas Santa Fe Drive, Suite 300, Solana Beach, CA, USA, 92075
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.